Supawat Thongthip Profile - Truist Financial Analyst
4 Followers
Supawat Thongthip Truist Financial
Wall Street Analyst
Success Rate
7 out of 13 ratings made a profit
Average Return
+4.00%
Average return per rating
Time Frame
Compare to
Copying Supawat Thongthip's trades since 2026 and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of 4.0% per rating.
Stock Rating Distribution
100.00% Buy
0.00% Hold
0.00% Sell
Distribution of Supawat Thongthip's ratings
Additional Information
Main Sector:General
Geo Coverage:
Best Rating
The most profitable rating made by Supawat Thongthip
Supawat Thongthip's Stock Coverage
Arcus Biosciences
Aug 06, 2026
Buy
Reiterated
―
4Ratings
+12.13%
Janux Therapeutics Inc
Aug 07, 2026
Buy
Reiterated
―
2Ratings
+6.10%
Immunome
Aug 12, 2026
Buy
Reiterated
$38.00
(41.32% Upside)
3Ratings
+10.10%
Sutro Biopharma
Aug 13, 2026
Buy
Reiterated
$50.00
(141.25% Upside)
3Ratings
-12.43%
ArriVent BioPharma, Inc.
Aug 13, 2026
Buy
Reiterated
$45.00
(53.58% Upside)
1Ratings
-1.60%
List of latest recommendations made by Supawat Thongthip. Click to expand and see Supawat Thongthip's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >About Analyst Ratings
About Analyst Ratings
Analyst ratings represent professional recommendations - Buy, Hold, or Sell - issued for a specific stock. Each rating reflects the analyst’s view at the time of publication and is tracked to measure historical performance.
Ratings Count
The total number of analyst ratings (Buy, Hold, and Sell) issued for the stock. This includes all published recommendations, even those not used in performance calculations.
Performance Calculation
To ensure accuracy and prevent duplication, only certain ratings are included in performance metrics:
•
One rating per analyst per month: If an analyst publishes more than one rating in a month, only the first is counted.
•
Updated ratings end prior ones: If the analyst changes their stance during that month (for example, from Buy to Sell), performance tracking for the earlier rating stops immediately on the update date, and the new rating begins tracking from that point forward.
•
Hold ratings excluded: Hold recommendations are displayed on the chart but are not counted in performance or return calculations.
Example
If an analyst rates a stock Buy on April 1 and changes it to Sell on April 20, the Buy rating’s performance is measured from April 1 to April 20. From April 20 onward, only the Sell rating is tracked.
Success Rate
Indicates the percentage of performance-accounted ratings that generated a positive return during their active period. For example, if 6 out of 17 accounted ratings were profitable, the success rate is 35%.
Average Return
Represents the mean return per active rating - showing the average gain or loss an analyst’s recommendation produced while it was active.
Supawat Thongthip activity FAQ
What is the performance of Supawat Thongthip's recommendations?
The percentage of profitable recommendations made by Supawat Thongthip is 54%, and the average return per transaction is 4.00%.
What was Supawat Thongthip's most profitable rating?
Supawat Thongthip’s most profitable ratings was a buy on RCUS stock on May 18, 2026 - Today. The return on the trade was +25.90%.
Where can I see a list of stock analyst ratings?
You can see a list of daily stock analyst ratings here.
What are the most recommended stocks by analysts?
You can see a list of the most recommended stocks by analysts here